Last updated: March 11, 2026
What is the drug identified by NDC 27241-0241?
The National Drug Code (NDC) 27241-0241 corresponds to Asciminib, marketed under the brand name Scemblix. It is a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) in August 2021 for the treatment of chronic myeloid leukemia (CML). As a targeted therapy, Asciminib offers a novel mechanism—a STAMP inhibitor—that binds to the myristoyl pocket of BCR-ABL1.
What is the current market landscape for Asciminib (Scemblix)?
Asciminib entered a competitive landscape characterized by several other BCR-ABL inhibitors: imatinib (Gleevec), dasatinib (Sprycel), nilotinib (Tasigna), bosutinib (Bosulif), and ponatinib (Iclusig). These agents are established first or second-line therapies, with multi-billion-dollar markets.
Market Size
- Global CML drug market: estimated at USD 4 billion in 2022.
- U.S. CML treatment market: approximately USD 2 billion (IQVIA, 2022).
Asciminib's initial target is patients resistant or intolerant to other TKIs, estimated at about 15-20% of the CML population.
Competitive Position
Asciminib's unique mechanism may position it as a treatment for:
- Patients with resistance or intolerance to existing TKIs.
- Potentially, as a first-line option pending approval studies.
Key Milestones
- FDA approval date: August 2021.
- FDA label: for patients with Philadelphia chromosome-positive CML who have failed prior TKI therapy.
- Pricing: listed at USD 13,000 - USD 15,000 per month (per Novartis pricing disclosures).
What are the current pricing strategies for Asciminib?
As of mid-2022, Novartis set the list price at USD 13,000 for a 30-day supply, aligning with other targeted oncology therapies. Negotiated prices for payers are typically 10-30% lower. Managed care organizations likely negotiate prices around USD 9,000-USD 11,700 per month.
Price comparison with similar drugs
| Drug |
Monthly Cost (USD) |
Indication |
Market Share |
| Imatinib |
USD 10,000-USD 11,500 |
First-line CML |
Dominant, established drug |
| Dasatinib |
USD 8,500-USD 10,000 |
Second-line or resistant CML |
Major second-line option |
| Nilotinib |
USD 9,000-USD 11,000 |
Resistant/intolerant CML |
Competitive with Asciminib |
| Bosutinib |
USD 8,500-USD 10,500 |
Resistant CML |
Similar profile to Asciminib |
| Ponatinib |
USD 15,000 |
T315I mutation-positive CML |
Higher dosing, more toxicity risk |
What are the revenue and sales projections?
Short-term projections (2023-2025):
- Initial adoption will focus on resistant or intolerant patients—a rare subset estimated at 3,000-4,000 patients in the U.S.
- Year 1 (2022): USD 50 million in sales, driven by early access and market penetration.
- Year 3 (2025): USD 250-350 million, assuming 50% market share among eligible patients.
Long-term projections (2026-2030):
- Market penetration increase possible if approved for first-line use.
- Potential sales: USD 1 billion+, contingent upon regulatory approvals and market uptake.
Factors influencing revenue
- Efficacy and safety profile compared with existing TKIs.
- Additional approvals for frontline therapy.
- Competitive pricing strategies.
- Payer reimbursement policies.
What are key risks and barriers?
- Competition: Established TKIs with extensive safety data.
- Pricing pressure: Payors may push for discounts.
- Regulatory approvals: First-line approval remains pending.
- Market penetration: Resistance from physicians due to conservative prescribing habits.
Summary
| Aspect |
Details |
| Current market size |
USD 2 billion (U.S. CML market 2022) |
| Pricing |
USD 13,000/month list, negotiated USD 9,000-USD 11,700 |
| 2022 sales estimate |
USD 50 million |
| 2025 sales forecast |
USD 250-USD 350 million |
| Long-term sales potential |
USD 1+ billion contingent upon approval and market acceptance |
Key Takeaways
- Asciminib entered a mature, competitive CML market with established first-line therapies.
- Its unique mechanism may offer an edge in resistant/relapsed patient populations.
- Pricing aligns with other targeted oncology drugs, with discounts likely for payers.
- Revenue growth depends on label expansion, market acceptance, and pricing strategies.
- Early adoption will be limited by the size of the resistant/intolerant population but could expand if approved for frontline use.
FAQs
1. How does Asciminib differ from other BCR-ABL inhibitors?
Asciminib binds to a different site (myristoyl pocket), offering activity in resistant mutations not responsive to traditional TKIs.
2. What is the expected timeline for market expansion?
Regulatory review for first-line use is ongoing; approval could occur within 2-3 years, potentially expanding market size.
3. How competitive is Asciminib's pricing?
Pricing is comparable to similar agents; discounts will likely be negotiated with payers, influencing overall revenue.
4. What are potential barriers to Asciminib’s market growth?
High competition, conservative physician prescribing, reimbursement challenges, and regulatory delays.
5. What is the potential impact of upcoming biosimilars or generics?
Currently, biosimilars for TKIs are not available; generics could enter the market if patents expire, but timelines are uncertain.
References:
- FDA (2021). FDA Approves Scemblix for Chronic Myeloid Leukemia. U.S. Food and Drug Administration.
- IQVIA (2022). Pharmaceutical Market Data.
- Novartis (2021). Scemblix Pricing and Access Details.
- MarketWatch (2022). Oncology Drug Market Size and Trends.
- WHO (2022). Global Cancer Statistics.
[1] Food and Drug Administration. (2021). FDA approves Scemblix for chronic myeloid leukemia. https://www.fda.gov
[2] IQVIA. (2022). U.S. pharmaceutical market data report.
[3] Novartis. (2021). Product pricing disclosures.
[4] MarketWatch. (2022). Oncology drug market analysis.
[5] World Health Organization. (2022). Cancer statistics.
